Conundrums in Managing Early Stages of Schizophrenia

  • Lena PalaniyappanEmail author
  • Priyadharshini Sabesan
  • Ross Norman
  • Alkomiet Hasan


Schizophrenia continues to be one of the most consuming mental illnesses, in terms of both the personal disability caused and the economic burden imposed on an individual and the society. While the provision of early intervention services has greatly enhanced the pathways of care provided, several challenges remain in clinical assessment and management during the early stages that pose critical questions for a clinician. Informed decision-making at these junctures is crucial to favorably alter the course of long-term outcomes. The following chapter will review clinical features of the early stages of schizophrenia, along with a discussion of evidence-based treatment approaches. Additionally, we highlight the role of a primary care physician in managing early stages of psychosis. Given the criticality of early intervention for long-term outcome, we discuss the malleable clinical factors that influence the trajectory of schizophrenia using a case example.


Schizophrenia Prodrome Antipsychotics Negative symptoms Relapse 


Disclosure Statement

Alkomiet Hasan has received paid speakership by Desitin, Otsuka and Janssen Cilag. He was a member of the Roche, Lundbeck and Janssen-Cilag Advisory Board. Lena Palaniyappan has received paid speakership by Otsuka / Lundbeck. Other authors declare no conflicts.


  1. 1.
    Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;(22):39–44.Google Scholar
  2. 2.
    Alvarez-Jimenez M, Gleeson JF, Henry LP, Harrigan SM, Harris MG, Amminger GP, McGorry PD. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr Res. 2011;125(2–3):236–46. S0920-9964(10)01595-1 [pii].CrossRefPubMedGoogle Scholar
  3. 3.
    Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, McGorry PD, Gleeson JF. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139(1–3):116–28. S0920-9964(12)00259-9 [pii].CrossRefPubMedGoogle Scholar
  4. 4.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 1994.Google Scholar
  5. 5.
    Anderson KK, Fuhrer R, Malla AK. The pathways to mental health care of first-episode psychosis patients: a systematic review. Psychol Med. 2010;40(10):1585–97. S0033291710000371 [pii].CrossRefPubMedGoogle Scholar
  6. 6.
    Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–20. S0140-6736(16)30272-0 [pii].CrossRefPubMedGoogle Scholar
  8. 8.
    Bertelsen M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, le Quach P, Christensen TØ, Krarup G, Jørgensen P, Nordentoft M. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry. 2008;65(7):762–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. Br J Psychiatry Suppl. 2005;48:s116–9. 187/48/s116 [pii].CrossRefPubMedGoogle Scholar
  10. 10.
    Birchwood M, Spencer E, McGovern D. Schizophrenia: early warning signs. Adv Psychiatr Treat. 2000;6:93–101.CrossRefGoogle Scholar
  11. 11.
    Cannon TD, Yu C, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, Heinssen R, Jeffries CD, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Kattan MW. An individualized risk calculator for research in prodromal psychosis. Am J Psychiatry. 2016;173(10):980–8. Scholar
  12. 12.
    Correll CU, De Hert M. Antipsychotics for acute schizophrenia: making choices. Lancet. 2013;382(9896):919–20. S0140-6736(13)61032-6 [pii].CrossRefPubMedGoogle Scholar
  13. 13.
    Craig TK, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, Dunn G. The Lambeth early onset (LEO) team: randomized controlled trial of the effectiveness of specialized care for early psychosis. Br Med J. 2004;329(7474):1067.CrossRefGoogle Scholar
  14. 14.
    Cropley VL, Pantelis C. Using longitudinal imaging to map the ‘relapse signature’ of schizophrenia and other psychoses. Epidemiol Psychiatr Sci. 2014;23(3):219–25. S2045796014000341 [pii].CrossRefPubMedGoogle Scholar
  15. 15.
    De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52–77.CrossRefGoogle Scholar
  16. 16.
    De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–24. S0924-9338(09)00017-0 [pii].CrossRefPubMedGoogle Scholar
  17. 17.
    Early Psychosis Guidelines Writing Group, & and EPPIC National Support Program. Australian clinical guidelines for early psychosis. 2nd ed. Melbourne: Orygen, The National Centre of Excellence in Mental Health; 2016.Google Scholar
  18. 18.
    Fortney JC, Unutzer J, Wrenn G, Pyne JM, Smith GR, Schoenbaum M, Harbin HT. A tipping point for measurement-based care. Psychiatr Serv. 2017;68(2):179–88. Scholar
  19. 19.
    Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220–9. 69/3/220 [pii].CrossRefPubMedGoogle Scholar
  20. 20.
    Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, De Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkötter J, McGuire P, Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiat. 2013;70(1):107–20. 1392281 [pii].CrossRefGoogle Scholar
  21. 21.
    Government of Ontario. Early psychosis intervention program standards. Toronto: Services Ontario; 2011.Google Scholar
  22. 22.
    Gray R, Wykes T, Edmonds M, Leese M, Gournay K. Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia: cluster randomised controlled trial. Br J Psychiatry. 2004;185:157–62. 185/2/157 [pii].CrossRefPubMedGoogle Scholar
  23. 23.
    Haddad PM, Kishimoto T, Correll CU, Kane JM. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry. 2015;28(3):216–21. Scholar
  24. 24.
    Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodríguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K Jones PB. (2003). The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;416:16–23.
  25. 25.
    Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–78. Scholar
  26. 26.
    Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16(3):142–70. Scholar
  27. 27.
    Hasan A, Wobrock T, Gaebel W, Janssen B, Zielasek J, Falkai P. [National and international schizophrenia guidelines. Update 2013 regarding recommendations about antipsychotic pharmacotherapy]. Nervenarzt. 2013;84(11):1359–60, 1362–54, 1366–58.
  28. 28.
    Ising HK, Veling W, Loewy RL, Rietveld MW, Rietdijk J, Dragt S, Klaassen RM, Nieman DH, Wunderink L, Linszen DH, van der Gaag M. The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population. Schizophr Bull. 2012;38(6):1288–96. sbs068 [pii].CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, Veijola J, Miettunen J. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296–306. sbs130 [pii].CrossRefPubMedGoogle Scholar
  30. 30.
    Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–97. S0140-6736(08)60486-9 [pii].CrossRefPubMedGoogle Scholar
  31. 31.
    Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, Addington J, Brunette MF, Correll CU, Estroff SE, Marcy P, Robinson J, Meyer-Kalos PS, Gottlieb JD, Glynn SM, Lynde DW, Pipes R, Kurian BT, Miller AL, Azrin ST, Goldstein AB, Severe JB, Lin H, Sint KJ, John M, Heinssen RK. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am J Psychiatry. 2016;173(4):362–72. Scholar
  32. 32.
    Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2010;36(6):1115–30. sbp031 [pii].CrossRefPubMedGoogle Scholar
  33. 33.
    Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103. sbp130 [pii].CrossRefPubMedGoogle Scholar
  34. 34.
    Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry. 2014;75(Suppl 1):8–14. Scholar
  35. 35.
    Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62. S0140-6736(13)60733-3 [pii].CrossRefPubMedGoogle Scholar
  36. 36.
    National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults: the NICE guideline on treatment and management. London: National Institute for Health and Care Excellent; 2014.Google Scholar
  37. 37.
    Norman RM, Malla AK. Prodromal symptoms of relapse in schizophrenia: a review. Schizophr Bull. 1995;21(4):527–39.CrossRefPubMedGoogle Scholar
  38. 38.
    Norman RM, Manchanda R, Malla AK, Windell D, Harricharan R, Northcott S. Symptom and functional outcomes for a 5 year early intervention program for psychoses. Schizophr Res. 2011;129(2–3):111–5. S0920-9964(11)00212-X [pii].CrossRefPubMedGoogle Scholar
  39. 39.
    Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiat. 2015;72(12):1172–81. 2466831 [pii].CrossRefGoogle Scholar
  40. 40.
    Palaniyappan L, White TP, Liddle PF. The concept of salience network dysfunction in schizophrenia: from neuroimaging observations to therapeutic opportunities. Curr Top Med Chem. 2012;12(21):2324–38.CrossRefPubMedGoogle Scholar
  41. 41.
    Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247–53. 62/3/247 [pii].CrossRefPubMedGoogle Scholar
  42. 42.
    Petersen L, Jeppesen P, Thorup A, Abel MB, Ohlenschlaeger J, Christensen TO, Krarup G, Jørgensen P, Nordentoft M. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. Br Med J. 2005;331(7517):602.CrossRefGoogle Scholar
  43. 43.
    Remington G, Agid O, Foussias G, Hahn M, Rao N, Sinyor M. Clozapine’s role in the treatment of first-episode schizophrenia. Am J Psychiatry. 2013;170(2):146–51. 1566895 [pii].CrossRefPubMedGoogle Scholar
  44. 44.
    Ruther T, Bobes J, De Hert M, Svensson TH, Mann K, Batra A, Gorwood P, Moller HJ. EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry. 2014;29(2):65–82. S0924-9338(13)00443-4 [pii].CrossRefPubMedGoogle Scholar
  45. 45.
    Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, Leucht S. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiat. 2016;73(3):199–210. 2488040 [pii].CrossRefGoogle Scholar
  46. 46.
    Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry. 2015;172(7):617–29. 10.1176/appi.ajp.2015.14101329.
  47. 47.
    Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rossler A, van der Gaag M, Meneghelli A, Nordentoft M, Marshall M, Morrison A, Raballo A, Klosterkötter J, Ruhrmann S. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry. 2015;30(3):388–404. S0924-9338(15)00057-7 [pii].CrossRefPubMedGoogle Scholar
  48. 48.
    Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, Camuri G, Altamura AC, Murray R, Bhattacharyya S. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(3):215–25. S2215-0366(15)00363-6 [pii].CrossRefPubMedGoogle Scholar
  49. 49.
    Schulz M, Gray R, Spiekermann A, Abderhalden C, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: a multi-centre randomised controlled trial. Schizophr Res. 2013;146(1–3):59–63. S0920-9964(13)00066-2 [pii].CrossRefPubMedGoogle Scholar
  50. 50.
    Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry. 2012;2:e82. tp20123 [pii].CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75–85.CrossRefPubMedGoogle Scholar
  52. 52.
    Windell DL, Norman R, Lal S, Malla A. Subjective experiences of illness recovery in individuals treated for first-episode psychosis. Soc Psychiatry Psychiatr Epidemiol. 2015;50(7):1069–77. Scholar
  53. 53.
    Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.CrossRefPubMedGoogle Scholar
  54. 54.
    Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205–18. S1461145712001277 [pii].CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Lena Palaniyappan
    • 1
    Email author
  • Priyadharshini Sabesan
    • 2
  • Ross Norman
    • 1
  • Alkomiet Hasan
    • 3
  1. 1.PEPP Program, London Health Sciences Centre, Robarts Research Institute and Department of Psychiatry, University of Western OntarioLondonCanada
  2. 2.Urgent Care and Ambulatory Mental Health, London Health Sciences Centre and University of Western OntarioLondonCanada
  3. 3.Department of Psychiatry and PsychotherapyKlinikum der Universität München, Ludwig-Maximilians Universität MünchenMunichGermany

Personalised recommendations